Short Interest in Burning Rock Biotech Limited (NASDAQ:BNR) Drops By 6.6%

Burning Rock Biotech Limited (NASDAQ:BNR) was the recipient of a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 60,500 shares, a drop of 6.6% from the December 31st total of 64,800 shares. Based on an average daily volume of 26,300 shares, the short-interest ratio is presently 2.3 days. Approximately 0.7% of the company’s shares are sold short.

Burning Rock Biotech Price Performance

BNR stock traded down $0.05 on Monday, reaching $6.64. 6,883 shares of the company traded hands, compared to its average volume of 5,278. Burning Rock Biotech has a one year low of $2.62 and a one year high of $8.99. The firm has a fifty day simple moving average of $6.66 and a 200-day simple moving average of $5.32. The company has a market cap of $67.97 million, a P/E ratio of -2.21 and a beta of 0.55.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings results on Tuesday, December 3rd. The company reported ($0.50) EPS for the quarter. Burning Rock Biotech had a negative net margin of 83.50% and a negative return on equity of 60.68%.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.